Trypaflavin bromide
Based on 1 Customer Validation
Trypaflavin bromide is an orally active acridine compound and antimalarial agent. Trypaflavin bromide invades germ cells. Trypaflavin bromide induces aberrations in unfertilized oocytes. Trypaflavin bromide increases the frequency of chromosomal aberrations. Trypaflavin bromide shows weak mutagenicity. Trypaflavin bromide is highly toxic to Leishmania, causing immediate lysis of the leptomonads.
For research use only. We do not sell to patients.
- Purity: 97.27%
- CAS No.: 857613-80-0
- Formula: C14H14BrN3
- Molecular Weight:304.19
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Infection Compound Library
HY-L002
-
Endocrinology Compound Library
HY-L047
-
Orally Active Compound Library
HY-L061
-
Antiparasitic Compound library
HY-L082
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
All Parasite Isoforms
More
Biological Activity
Trypaflavin (2 mg/kg/day; p.o.; 50 days) bromide slightly elevates preimplantation egg loss and dead implants without inducing significant dominant lethal mutations in female C3H mice, and weakly increases total chromosome aberration frequencies to 21.1% in metaphase-II oocytes of female NMRI mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C3H (female; parental generation; pregnant; prenatal in utero treatment to target oogonia/early meiotic oocyte stages); C3H F1 (female; 10 weeks old at mating)[1]
-
Dosage:50 mg/kg
-
Administration:p.o.; single acute dose; day 7, 11, 14, or 15 post conception
-
Result:Induced significant mutagenic effects only with day 7 post conception treatment: Increased preimplantation egg loss to 24.9%.
Increased dead implants per female to 1.4.
Decreased living embryos per female to 7.2.
Induced dominant lethal mutations of 13.25.
Showed no significant effects with treatment on days 11, 14, or 15 post conception.
-
Animal Model:C3H (female; 3 weeks old at study start)[1]
-
Dosage:2 mg/kg/day
-
Administration:p.o.; daily; 50 days
-
Result:Increased preimplantation egg loss to 13.3%.
Increased dead implants per female to 2.2.
Induced dominant lethal mutations of -1.27.
-
Animal Model:NMRI (female; 3 weeks old at study start)[1]
-
Dosage:2 mg/kg/day
-
Administration:p.o.; daily; at least 50 days
-
Result:Increased the frequency of aberrant metaphase-II oocytes to 21.1%, aneuploidies to 13.5%, structural aberrations including gaps to 9.3%, and structural aberrations excluding gaps to 8.1%.
Increased yield of all aberration types (aneuploidies, gaps, breaks and fragments, satellite associations, deletions, interchanges).
Chemical Information
-
CAS No. 857613-80-0
-
Appearance Solid
-
Molecular Weight 304.19
-
Formula C14H14BrN3
-
Color Orange to reddish brown
-
SMILES
NC1=CC=C2C=C3C=CC(N)=CC3=[N+](C)C2=C1.[Br-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Trypaflavin bromide Related Classifications
HY-B1509B Related Classifications
Powered by Bioz